Predictive Oncology Inc.’s (NASDAQ: POAI) TumorGenesis Partners with Cellevate for New Approach to Ovarian Cancer
Collaboration will use TumorGenesis’ expertise in cancer cell culture growth media in combination with Cellevate’s specialty in emerging field of nanofiber matrixes. Cutting-edge technology can help avoid mistakes in $2.6 billion process of bringing new drugs through FDA process. Coupling companies’ technology will give researchers ability to grow ovarian cancer tissues in 3D matrix support … Continue reading “Predictive Oncology Inc.’s (NASDAQ: POAI) TumorGenesis Partners with Cellevate for New Approach to Ovarian Cancer”